User:Camarieslagle/sandbox

Name of original article: Bone marrow failure

-adding section on epidemiology

-add medications for treatment

Also upon wiki, treating anemia related condition due to bone marrow failures. See below.

“ Description- Metenolone enanthate, or methenolone enanthate, sold under the brand names Primobolan Depot and Nibal Injection, is an androgen and anabolic steroid medication which is used mainly in the treatment of anemia due to bone marrow failure”

Epidemiology
For those with severe bone marrow failure, the cumulative incidence of resulting stem cell transplantation or death was greater than 70% by individuals 60 years of age. The incidence of bone marrow failure is triphasic: one peak at two to five years during childhood (due to inherited causes), and two peaks in adulthood, between 20 to 25 years old and after 60 years old (from acquired causes). One in ten individuals with bone marrow failure have unsuspected FA. FA is the most common inherited bone marrow failure with an incidence of one to five episodes per million individuals. The carrier frequency for FA is 1 in 200 to 300, however this differs by ethnicity as shown in Table 1 below. In Europe and North America, the incidence of acquired aplastic anemia is rare with two episodes per million people each year, yet in Asia rises with 3.9 to 7.4 episodes per million people each year. While acquired aplastic anemia with an unknown cause is rare, it is commonly permanent and life threatening as half of those with this condition die within the first six months.

The prevalence of bone marrow failure is over three times higher in Japan and East Asia than in the United States and Europe. Myelodysplastic syndromes (MDS) is a form of blood cancer found within the bone marrow in which the body no longer produces enough healthy, normal blood cells. MDS are a frequently unrecognized and rare group of bone marrow failure disorders, yet the incidence rate has rose from 143 reported cases in 1973 to approximately 15,000 cases in the United States each year. Although MDS is often under-diagnosed, leading the believed actual incidence rate to be estimated at 35,000 to 55,000 new cases annually. One in three people with MDS progress to acute myeloid leukemia. For lower risk patients, those who do not undergo a bone marrow transplant have an average survival rate of up to six years. However, high-risk patients have a survival rate of approximately five months. When one's body fails to produce blood cell lines, the morbidity and mortality rate increases.